Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
Conditions: Head and Neck Carcinoma of Unknown Primary; Locally Advanced Head and Neck Squamous Cell Carcinoma; Locally Advanced Hypopharyngeal Squamous Cell Carcinoma; Locally Advanced Laryngeal Squamous Cell Carcinoma; Locally Advanced Nasopharyngeal Squamous Cell Carcinoma; Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Interventions: Drug: Tolinapant; Radiation: Radiation Therapy
Sponsors: Emory University; Astex Pharmaceuticals, Inc.
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
February 22, 2022 /
/ in Oncology